Skip to content

Patients › Hand

Giant Cell Tumour of Tendon Sheath (Lump on a Finger or Thumb)

PDF In-depth PDF Evidence

A giant cell tumour of tendon sheath is a common, benign (non-cancerous) lump on a finger or thumb. What causes it, how it is diagnosed and removed, and how often it comes back.

Updated Sep 20265 citations
A hand-drawn illustration of a benign soft lump on the side of a finger.
Under the microscope, a giant cell tumour of tendon sheath is made up of clusters of multinucleated giant cells (the dark, lumpy-looking cells) mixed with smaller mononuclear cells. It is benign, and it is this giant-cell appearance that gives the lesion its name. Kieran Hirpara 4.0

What you're feeling

You may have noticed a small, firm lump on one of your fingers or your thumb. It is usually not tender, and it often feels fixed in place rather than moving around under the skin. The lump can be smooth or slightly lumpy in shape.

Most of these lumps sit near a joint. The joint at the very end of the finger is a common spot, and the lump can appear on the back, front, or side of the finger. The index finger is affected more often than the others.

For many people, the lump itself causes little trouble. Pain is not always part of it, but when it does occur, it tends to sit right at the lump or in the nearby joint. Some people notice catching or locking in the finger, or swelling around a joint. A small number feel tingling or numbness if the lump presses on a nearby nerve.

Because the lump sits close to the tendons, the cords that glide your finger as you move it, some daily tasks can become awkward. You might find it harder to grip a jar lid, hold a pen comfortably, type, or button clothing. Anything that bends or squeezes the finger where the lump sits can make it more noticeable.

These lumps grow slowly. Many people live with one for months or even years before having it looked at. There is no typical pattern of flaring at night or on waking, and nothing you do is making it worse.

A few points worth knowing. This kind of lump is benign, which means it is not a cancer and does not spread to other parts of the body. It is also common: it appears more often in women than men, and it usually shows up between the ages of about 32 and 51, though it can appear earlier or later. It is not usually linked to an injury.

The main thing to sort out with your surgeon is removing the lump completely, because these lumps can grow back if any tissue is left behind.

What's actually happening

Your finger has two thin cords, called tendons, that run from your palm to your fingertip. They work like the strings that pull a puppet's fingers: when the muscle pulls, the tendon glides and the finger bends. Each tendon slides inside a smooth sleeve, a bit like a gasket around a moving pipe, that keeps the gliding easy.

A giant cell tumour of the tendon sheath is an overgrowth of the tissue that makes up that sleeve. The name sounds alarming, but it describes what the tissue looks like under a microscope, not what it does. It is benign, not a cancer. The lump grows slowly from the sheath itself, which is why it feels fixed in place rather than rolling under the skin.

As the lump gets bigger, it presses on the things around it. That explains most of what you have noticed. Pressure on the tendon can cause catching or locking, and swelling around the nearby joint. Pressure on a nerve can cause tingling or numbness. Pain is less common than you might expect, and many of these lumps never hurt at all.

There are two broad patterns. Most lumps are a single, well-defined nodule with a clear edge, like a pea in a capsule. The rest are made up of two or more separate pieces that are not joined together, which matters because the scattered pieces are harder to remove completely. Occasionally the lump presses into the bone next to it, leaving a shallow dent rather than eating into it.

Nobody knows exactly why this overgrowth starts. The accepted thinking is that the sheath tissue reacts to some irritation and starts multiplying, and genes may play a part as well. An injury is only rarely the trigger.

The practical point is simple: the lump is a local problem in one spot on your finger, and the aim of treatment is to remove all of it so it does not grow back.

What we can do about it

Dr Kieran Hirpara, an upper-limb surgeon at Mater Private Hospital Rockhampton, starts with the least invasive options that suit your condition. Patients are generally referred to our clinic by their GP; if a physiotherapist has suggested you see us, you will still need a referral from your GP in order to be eligible for the Medicare rebate. At your first visit we take a history, examine your finger, and arrange imaging such as a scan if it is needed to confirm what the lump is.

For a lump like this, there is little for you to try at home that will make it shrink. If the lump is catching or making some tasks awkward, we may suggest changing how you use that hand for a while. Hand therapy aims to keep the finger moving comfortably and to settle any irritation in the tendon next to the lump. We usually give this a fair trial before thinking about anything further.

These lumps are not caused by inflammation, so pain tablets and anti-inflammatories will not shrink the lump itself. If the lump is uncomfortable, simple pain relief can settle things while you wait for assessment.

Most of these lumps do not disappear on their own, and the accepted treatment is to remove the lump completely. Because the lump grows from the tendon sheath, surgery aims to take out the lump along with the small patch of sheath it is attached to. Removing that attachment site matters: when it is taken with the lump, these lumps have not grown back over an average of about three years afterwards. If any tissue is left behind, the lump can grow back, and about one in seven people need a second operation for this reason. Lumps made up of two or more separate pieces are more likely to grow back than single lumps, so we take extra care with those.

Surgery is a shared decision between you and us. If the lump is small, not painful, and not getting in the way, watching it is a reasonable choice. If it is growing, catching, pressing on a nerve, or bothering you each day, removing it is usually the next step. The operation itself has its own page, which explains what it involves and what recovery looks like.

What to expect

The outlook for this lump is steady rather than dramatic. It is benign, so it does not spread anywhere else in your body. It also grows slowly, and most lumps do not disappear on their own. If you leave it alone, it usually stays much the same or keeps growing bit by bit, which is why many people eventually choose to have it removed.

The main thing to plan for is the chance of the lump growing back. About one in seven people need a second operation because some tissue was left behind the first time. When it does grow back, it usually happens within 36 months of the first removal. Some lumps are more likely to return than others: lumps made of two or more separate pieces, and lumps that have grown into the tendon or the joint capsule, the sleeve around the joint itself. If yours is one of these, your surgeon will keep a closer eye on you afterwards.

When the lump is removed completely, the results hold up well over time. People who have this surgery generally keep good use of their hand, with function measured at 92% of normal in one group followed afterwards. Some people in that group had a similar lump deeper in a joint, treated with keyhole surgery, and were still free of it close to seven years later. For a related but rarer lump on the tendon sheath, removing it along with its attachment site has meant no regrowth over an average of about three years.

If the lump turns out to be the kind that spreads more widely through the sheath, or if it grows back after surgery, there are still options. Radiation therapy, a targeted course of X-ray treatment, can sometimes control the lump while keeping your hand working normally.

So the realistic picture is this: the lump will not go away by itself, removal works well for most people, and the main thing to watch for in the years afterwards is regrowth, usually inside the first three years.

When to see someone

See your GP if you have a firm lump on a finger or thumb that has not gone away after a few weeks, or if it is slowly getting bigger. Ask for a specialist review if the lump is catching or locking, if the joint around it is swollen, or if you notice tingling or numbness in the finger, which can mean the lump is pressing on a nerve. Pain is less common with this condition, but a lump that has become tender or is getting in the way of your work or daily tasks is also worth having assessed. These lumps are benign, so there is no emergency here, and nothing about them spreads. The main reason not to wait years is that the longer a lump sits next to the tendon, the more it can press on the structures around it, and a smaller lump is simpler to remove completely.

In more depth

Advanced reading: the deeper science (optional)

This section goes further than you need for your own treatment decisions. Giant cell tumour of the tendon sheath is worth the extra reading because its defining problem is recurrence, and the evidence suggests recurrence is driven more by the biology of the individual tumour than by anything about how it is removed.

Recurrence is a property of the tumour, not only of the surgery

The instinctive explanation for a lump coming back is that some was left behind. A systematic review of 605 digital cases concluded otherwise: the intrinsic biology of the tumour appears to play a more fundamental role in recurrence than tumour location or local invasiveness, with the authors calling for larger prospective studies to identify which tumours are prone to recurrence [1].

That is a genuinely useful thing to be told before an operation. Recurrence after a well-performed excision is a recognised behaviour of this tumour rather than evidence that something went wrong.

Treatment is elective, and doing nothing is a real option

It is easy to lose sight of this once an operation is being planned. The principle of first-line treatment is complete resection, but treatment is never urgent, and the indication should be weighed against symptoms, progression, location and your own circumstances [4].

For a small, painless, slowly growing nodule, watching it is a legitimate choice. The tumour is benign and does not spread, so the argument for operating is about function, size and nuisance — not about danger.

But two surgical factors do matter

Biology is not the whole story. In 941 patients with localised-type tenosynovial giant cell tumour, the factors associated with recurrence after resection were larger tumour size and initial treatment with arthroscopy. Given relatively low complication rates and good functional outcomes, the authors recommend an open approach with complete resection where possible to reduce recurrence in high-risk cases [2].

The counterpoint is that arthroscopic excision has been shown effective for the localised type across four joints in a review of 1,448 patients, while in the diffuse type, arthroscopic synovectomy has demonstrated efficacy only at the knee [3].

Reconciling these: for a small, localised, well-defined lesion, either approach can work. As size increases, and for the diffuse form, complete open excision is better supported. The reason is mechanical, this tumour extends in fronds around tendon, nerve and joint, and the parts most easily missed are the ones tucked behind structures that must be lifted and inspected directly.

Why the naming matters

The condition now sits under tenosynovial giant cell tumour, which covers both the localised form in the hand and the diffuse intra-articular form previously called pigmented villonodular synovitis [4]. They are the same entity in different locations and growth patterns.

This is worth knowing if you read around the subject, because a search will return material about knees and hips that is describing your condition in its diffuse form, and the recurrence rates quoted for the diffuse disease are considerably higher than those for a localised digital lesion. Applying knee figures to a finger lump overstates the risk.

Where radiotherapy sits

For diffuse disease that has recurred or cannot be completely excised, adjuvant radiotherapy is sometimes considered. A meta-analysis found that open synovectomy, or synovectomy combined with perioperative radiotherapy, was associated with a reduced rate of recurrence in diffuse pigmented villonodular synovitis, while calling for large long-term prospective studies to confirm it [5].

For a localised digital tumour, which is the great majority of hand cases, this does not arise. It belongs to the diffuse, recurrent, joint-based end of the spectrum, and is mentioned here only because a search on the condition name will surface it.

What it is not

Despite the name, this is a benign tumour. It does not spread elsewhere in the body. The word "tumour" carries weight it does not deserve here, and the concern with recurrence is about repeated local surgery, stiffness and nerve proximity, not about cancer.

Reviewed by Kieran Hirpara · 28 April 2026.

Talk to your treating clinician for advice specific to you.

For an appointment with the CQ Hand + Upper Limb team, ask your GP about a referral or visit www.cqupperlimb.com.

References for the advanced reading
  1. Fotiadis E, Papadopoulos A, Svarnas T, Akritopoulos P, Sachinis NP, Chalidis BE. Giant cell tumour of tendon sheath of the digits. A systematic review. Hand (N Y). 2011;6(3):244-9.
  2. Mastboom M, Staals E, Verspoor F, Rueten-Budde A, Stacchiotti S, Palmerini E, et al. Surgical treatment of localized-type tenosynovial giant cell tumors of large joints: a study based on a multicenter-pooled database of 31 international sarcoma centers. J Bone Joint Surg Am. 2019;101(14):1309-18.
  3. Noailles T, Brulefert K, Briand S, Longis P, Andrieu K, Chalopin A, et al. Giant cell tumor of tendon sheath: open surgery or arthroscopic synovectomy? A systematic review of the literature. Orthop Traumatol Surg Res. 2017;103(5):809-14.
  4. Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop Traumatol Surg Res. 2017;103(1):S91-S97.
  5. Mollon B, Lee A, Busse JW, Griffin AM, Ferguson PC, Wunder JS, et al. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee. Bone Joint J. 2015;97-B(4):550-7.
Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

  • Giant cell tumors of the tendon sheaths in the hand are benign lesions [2].
  • Recurrence is the primary risk for giant cell tumors of the tendon sheaths in the hand [2].
  • Recurrence for giant cell tumors of the tendon sheaths typically occurs within 36 months of excision [2].
  • Giant cell tumors of the synovial sheaths in the hand are benign lesions [3].
  • Recurrence is the primary risk for giant cell tumors of the synovial sheaths in the hand [3].
  • Complete surgical resection remains the treatment of choice for most patients with tenosynovial giant cell tumors [7].
  • Diffuse tenosynovial giant cell tumor disease presents challenges due to high recurrence rates [7].
  • In cases of infiltrative GCTTS, radiation therapy may provide local tumor control with preservation of hand function [1].

Anatomy & Pathophysiology

Epidemiology & Demographics

  • Giant cell tumours of tendon sheath (GCTTS) are the second most common benign proliferative tumours in the upper extremities after ganglion cysts [65].
  • GCTTS are usually slow-growing, painless, benign, and consist of soft tissue [65].
  • GCTTS are most commonly found in the fingers and among women in their fourth and fifth decades [65].
  • In a systematic review of 605 patients, the male-to-female ratio for GCTTS of the digits was 1:1.47 [11].
  • In a study of 64 cases, the male-to-female ratio for GCTTS was 1:1.66 [25].
  • In a series of 12 patients, the mean age for GCTTS was 29.5 years, ranging from 10 to 53 years [23].
  • In a study of 64 cases, the age of patients ranged from 15 to 77 years with a mean age of 45 years [25].

Clinical Presentation & Location

  • GCTTS are usually asymptomatic, but as the tumour grows, patients may present with swelling, pain, and limitation of movement [65].
  • In a systematic review of 605 patients, pain was reported in 15.7% of cases and sensory disturbances in 4.57% [11].
  • In a systematic review of 605 patients, a definite history of trauma was recorded in 5% of lesions [11].
  • In a systematic review of 605 patients, the most frequent tumour location was the index finger (29.7%) [11].
  • In a study of 64 cases, the most frequent location of the tumor was the long finger in 23.5% of patients [25].
  • In a study of 64 cases, lesions were found over the thumb in 20.3% of patients [25].
  • In a study of 64 cases, lesions were found over the index finger in 20.3% of patients [25].
  • In a study of 64 cases, lesions were found over the hand in 20.3% of patients [25].
  • In a series of 12 patients, the most common presentation was with a mass over the hand, with a predilection to the thumb (n=7) [23].

Morphology & Histology

  • Type I GCTTS are defined as nodular or multinodular lesions surrounded by a capsule [65].
  • Type II GCTTS are defined as tumours with no connective tissue membrane and satellite, diffuse, or multicentric nodules [65].
  • In a systematic review of 605 patients, Type I tumours (single lesions) were detected in 78.7% of cases [11].
  • In a systematic review of 605 patients, Type II tumours (two or more distinct tumours that were not joined together) were detected in 21.3% of cases [11].
  • Microscopically, all GCTTS tumors contained multinucleated giant cells, histiocytes, and haemosiderin deposits [25].
  • Macroscopically, the average size of GCTTS tumors was 1.35 cm, with a range of 0.3 cm to 5 cm [25].

Pathogenesis & Etiology

  • GCTTS originate from the synovial membrane, tendon sheath, or synovial bursa [65].
  • The pathogenesis of GCTTS remains unclear [65].
  • Inflammation resulting from reactive or regenerative hyperplasia is the generally accepted theory of pathogenesis for GCTTS [65].
  • Genetic factors have been observed in previous studies regarding GCTTS pathogenesis [65].

Imaging & Local Invasion

  • Radiography can be helpful in evaluating cortical destruction but is not helpful in the definitive diagnosis of GCTTS [65].
  • Magnetic resonance imaging (MRI) is the most useful examination for the diagnosis and treatment planning of GCTTS [65].
  • In a series of 12 patients, radiological changes in the form of bony indentation were seen in only 2 cases [23].
  • In a study of 64 cases, bone erosion was found in 3 patients (4.7%) [25].
  • In a study of 64 cases, tendon involvement occurred in 7 cases (10.9%), with a flexor-to-extensor ratio of 4:3 [25].
  • In a study of 64 cases, involvement of the neurovascular bundle was presented in 7 patients (10.9%) [25].

Classification

  • Giant cell tumour of tendon sheath (GCTTS) is classified into two main types based on whether the entire tumour is surrounded by one pseudocapsule [56].
  • Type I GCTTS consists of single lesions [11].
  • Type II GCTTS consists of two or more distinct tumours that are not joined together [11].
  • Type I tumours were detected in 78.7% of patients in a systematic review of 605 patients [11].
  • Type II tumours were detected in 21.3% of patients in a systematic review of 605 patients [11].
  • In a prospective study of 43 cases, none of the 30 Type I tumours recurred [56].
  • In a prospective study of 43 cases, recurrence occurred in five out of 13 Type II tumours [56].
  • Second recurrences were observed with Type II B and C tumours but not with Type II A tumours [56].
  • Type II tumours are associated with a higher risk of recurrence compared to Type I tumours [11].
  • The Al-Qattan classification is used to classify GCTTS lesions based on capsule thickness, lobulation, satellite lesions, and diffuse or multicentric nature [23].

Clinical Presentation

  • Giant cell tumors of the tendon sheaths in the hand are benign lesions where recurrence is the primary risk [2].
  • Giant cell tumors of the synovial sheaths in the hand are benign lesions in which recurrence is the primary risk [3].
  • Pigmented villonodular synovitis and giant-cell tumor of tendon sheath are benign synovial neoplasms with the potential for local recurrence [38].
  • Patients with giant cell tumor of tendon sheath may present with a discrete mass or with joint swelling, pain, or locking or catching [26].
  • The most frequent tumour location for giant cell tumour of tendon sheath of the digits is the index finger, accounting for 29.7% of cases [11].
  • In a series of 91 finger tumors, 31 occurred at the distal joints, with 18 on the dorsal aspect and 13 distributed about evenly on the radial, ulnar, and volar aspects [22].
  • The tumors were usually firm, lobulated, and non-tender [22].
  • The masses were somewhat fixed [22].
  • Pain was reported in 15.7% of cases of giant cell tumour of tendon sheath of the digits [11].
  • Sensory disturbances were reported in 4.57% of cases of giant cell tumour of tendon sheath of the digits [11].
  • A definite history of trauma was recorded in 5% of lesions [11].
  • The male-to-female ratio for giant cell tumour of tendon sheath of the digits was 1:1.47 [11].
  • The mean age for giant cell tumour of tendon sheath of the digits ranged from 32 to 51 years [11].
  • Type I tumours (single lesions) were more frequently detected (78.7%) than type II tumours (two or more distinct tumours that were not joined together) (21.3%) [11].
  • Type II tumours were associated with higher recurrence rates [11].
  • The overall recurrence rate for giant cell tumour of tendon sheath of the digits was 14.8% [11].
  • The duration of symptoms for finger tumors ranged from two weeks to fifteen years, with an average duration of thirty-eight months [22].
  • In a series of 12 patients, the mean age was 29.5 years, ranging from 10 to 53 years [23].
  • Radiological changes in the form of bony indentation were seen in only 2 cases out of 12 [23].
  • Direct involvement of the extensor tendons, flexor tendons, or joint capsule puts patients in a high-risk category with respect to recurrence [21].

Investigations

  • MRI findings and location might help in the diagnosis of tenosynovial giant cell tumors, but careful assessment is mandatory, especially in unusual locations [84].
  • Radiologists should be familiar with the imaging characteristic of giant cell tumors of the mobile spine with invasion of adjacent vertebrae [87].

Treatment

Surgical Excision

  • Complete surgical resection is the treatment of choice for most patients with tenosynovial giant cell tumors [7].
  • Total surgical excision ensuring removal of the attachment site (flexor sheath/palmar fascia) resulted in no local recurrences at a mean follow-up of 3.2 years [8].
  • En bloc resection and matched nonvascularized toe phalangeal transfer resulted in a functional tumor-free digit with a low complication rate and no recurrences for Campanacci Grade 2 or 3 giant cell tumors of the phalanges [17].
  • Repeated curettage with adjuvants eventually resulted in the cure for all patients and is a reasonable treatment for both primary and recurrent GCT of the small bones of the hands and feet [68].
  • Intralesional excision with local adjuvant therapy is recommended for the treatment of giant cell tumor of bone because it results in a good functional outcome compared to extralesional excision [63].
  • Intralesional excision with cautery and methylmethacrylate provides a reliable method of treatment of giant cell tumors with good long-term functional results [37].
  • Intralesional excision remains a viable, and likely the standard, mode of treatment for most giant cell tumors of the distal radius unless there is extensive bone loss [6].
  • Intralesional excision appears to be more appropriate for the treatment of local lesions (eg, Grades 1 and 2) than Grade 3 GCTs of the distal radius [27].
  • Both curettage and resection/amputation are acceptable treatment options for the rare condition of giant cell tumour of bone in the hand, with a need to individualize treatment decisions based on the site and extent of disease to minimize treatment morbidity while maximizing disease control [4].
  • The distal ulna may be widely resected with or without stabilization of the residual ulnar stump, yielding satisfactory local disease control and functional outcome [24].
  • Reconstruction after wide excision by nonvascularized fibular graft is a viable alternative for giant cell tumors of the lower end of radius though it is a challenging procedure and may be accompanied by major complications [73].
  • The use of a massive biocompatible bipolar unconstrained prosthesis is a viable treatment option for distal radius reconstruction after en-bloc resection of a giant cell tumour, offering rapid functional improvement without donor-site morbidity [62].
  • This is a simple and effective modality of reconstruction after resection of distal radial tumors [13].
  • Aggressive and malignant bone tumors of the second through fifth metacarpals generally require en bloc bone excision [18].
  • It is essential that an adequate, safe margin of normal tissue first be excised en bloc with the tumor for aggressive and malignant bone tumors of the second through fifth metacarpals [18].
  • Wide en bloc excision of soft tissue sarcomas with negative margins is required to achieve local control of the lesion [18].
  • At a minimum, aggressive soft tissue tumors, such as bone tumors, require ray resection or removal of multiple rays [18].
  • Central palmar lesions more likely require sacrifice of three rays; those on the border are more likely than those in the center to be salvageable by removing just two rays [18].
  • In the presence of proximal, broader, and larger lesions, all four digits or the entire hand may have to be sacrificed to save the patient [18].
  • If a malignant tumor has broken into the midpalm and extends across the metacarpals, removal of all digital rays may be needed to gain an adequate soft tissue margin [18].
  • If a tumor extends proximally from the metacarpal level, a more proximal level of hand, wrist, or forearm amputation is required for safe tumor management [18].
  • Malignant soft tissue tumors in the palm or carpal tunnel often require at least partial hand amputation [18].
  • Below-elbow amputation is necessary to treat larger tumors [18].
  • This case offers a practical strategy for the surgical management of this rare hand tumor [5].

Recurrence and Risk Factors

  • Giant cell tumors of the tendon sheaths in the hand are benign lesions where recurrence is the primary risk, typically occurring within 36 months of excision [2].
  • In total, 14.8% of patients had tumour recurrence in a systematic review of giant cell tumour of tendon sheath of the digits [11].
  • Type II tumours (two or more distinct tumours that were not joined together) were associated with higher recurrence rates than Type I tumours (single lesions) [11].
  • Well-designed studies combining the recurrence rates of several hand surgery centers implementing a standardized treatment are needed to better demonstrate the associated risk factors for recurrence [12].
  • Diffuse disease presents challenges due to high recurrence rates for tenosynovial giant cell tumors [7].
  • Our recurrence rate was 4,7% (n=3) in a study of 64 cases of giant cell tumor of tendon sheath [25].
  • In 3 patients (4,7%) bone erosion was found, and in 7 cases (10,9%) tendon involvement was found in a study of 64 cases of giant cell tumor of tendon sheath [25].
  • In the three recurrence cases, surgical excision was difficult [25].
  • We recommend selective use of curettage and cementing in Grade III lesions, particularly with extensive soft tissue involvement [35].

Complications

  • The pooled recurrence rate for giant cell tumour of tendon sheath of the digits after surgical excision is 14.8% [11].
  • Type II tumours (two or more distinct tumours that were not joined together) are associated with higher recurrence rates than Type I tumours [11].
  • Direct involvement of the extensor tendons, flexor tendons, or joint capsule places patients in a high-risk category for recurrence [21].
  • Total surgical excision ensuring removal of the attachment site (flexor sheath/palmar fascia) resulted in no local recurrences at a mean follow-up of 3.2 years for fibroma of tendon sheath [8].
  • En bloc resection and matched nonvascularized toe phalangeal transfer for Campanacci Grade 2 or 3 giant cell tumor of the phalanges resulted in no recurrences [17].
  • Patients with giant cell tumor of bone who are at higher risk of recurrence should be clinically followed more closely [15].
  • Metachronous multicentric giant cell tumor can recur with a disease-free interval of up to 24 years [43].

Recovery

  • Recurrence for giant cell tumors of the tendon sheaths in the hand typically occurs within 36 months of excision [2].
  • Surgical treatment for pigmented villonodular synovitis led to good functional results with an average Enneking score of 92% of normal limb function [10].
  • Well-designed studies combining the recurrence rates of several hand surgery centers implementing a standardized treatment are needed to better demonstrate the associated risk factors for recurrence in giant cell tumor of tendon sheath [12].
  • Patients with pigmented villonodular synovitis of the hip managed with arthroscopic synovectomy reported good functional outcomes without evidence of recurrence in a 19 patient cohort with an average follow-up of almost 7 years [76].

Key Evidence

  • [L4] In cases of infiltrative GCTTS, radiation therapy may provide local tumor control with preservation of hand function. [1] (10.1016/j.jhsa.2012.01.011)
  • [L4] Giant cell tumors of the tendon sheaths in the hand are benign lesions where recurrence is the primary risk, typically occurring within 36 months of excision. [2] (10.1016/j.otsr.2013.03.008)
  • [L4] Giant cell tumors of the synovial sheaths in the hand are benign lesions in which recurrence is the primary risk. [3] (10.1016/j.jhsa.2013.08.051)
  • [L4] Both curettage and resection/amputation are acceptable treatment options for the rare condition of giant cell tumour of bone in the hand, with a need to individualize treatment decisions based on the site and extent of disease to minimize treatment morbidity while maximizing disease control. [4] (10.1177/17531934211007820)
  • [Paper] This case offers a practical strategy for the surgical management of this rare hand tumor. [5] (10.1177/15589447261480384)
  • [L3] Intralesional excision remains a viable, and likely the standard, mode of treatment for most giant cell tumors of the distal radius unless there is extensive bone loss. [6] (10.1007/s11999-014-4054-3)
  • [L5] Complete surgical resection remains the treatment of choice for most patients with tenosynovial giant cell tumors, though diffuse disease presents challenges due to high recurrence rates. [7] (10.5435/jaaos-d-24-01255)
  • [L4] Total surgical excision ensuring removal of the attachment site (flexor sheath/palmar fascia) resulted in no local recurrences at a mean follow-up of 3.2 years. [8] (10.1177/1753193412469146)
  • [L4] Surgical treatment led to good functional results with an average Enneking score of 92% of normal limb function. [10] (10.1097/01.blo.0000224051.01873.fb)
  • [L1] [11] (10.1007/s11552-011-9341-9)
  • [L3] Well-designed studies combining the recurrence rates of several hand surgery centers implementing a standardized treatment are needed to better demonstrate the associated risk factors for recurrence. [12] (10.1186/s12891-019-2866-8)
  • [L4] This is a simple and effective modality of reconstruction after resection of distal radial tumors. [13] (10.1016/j.jhsa.2022.05.011)
  • [L4] Our observations suggest there are subsets of patients with giant cell tumor of bone who are at higher risk of recurrence and should be clinically followed more closely. [15] (10.1007/s11999-011-2172-8)
  • [L4] En bloc resection and matched nonvascularized toe phalangeal transfer resulted in a functional tumor-free digit with a low complication rate and no recurrences. [17] (10.1016/j.jhsa.2024.06.013)
  • [L3] Direct involvement of the extensor tendons, flexor tendons, or joint capsule puts patients in a high-risk category with respect to recurrence. [21] (10.1016/j.jhsa.2009.12.004)
  • [L4] [22] (10.2106/00004623-196951010-00005)
  • [L4] [23] (10.1007/s12593-010-0020-9)
  • [L3] The distal ulna may be widely resected with or without stabilization of the residual ulnar stump, yielding satisfactory local disease control and functional outcome. [24] (10.1177/1558944717743598)
  • [L4] [25] (10.11138/gchir/2013.34.5.149)
  • [Case_report] [26] (10.1016/j.jhsa.2014.11.010)
  • [L3] Based on data obtained from the number of studies available, intralesional excision appears to be more appropriate for the treatment of local lesions (eg, Grades 1 and 2) than Grade 3 GCTs of the distal radius. [27] (10.1007/s11999-012-2464-7)
  • [L4] We recommend selective use of this procedure in Grade III lesions, particularly with extensive soft tissue involvement. [35] (10.4103/0019-5413.77138)
  • [L4] Intralesional excision with cautery and methylmethacrylate provides a reliable method of treatment of giant cell tumors with good long-term functional results. [37] (10.1097/01.blo.0000128280.59965.e3)
  • [L4] Pigmented villonoid synovitis and giant-cell tumor of tendon sheath are benign synovial neoplasms with the potential for local recurrence. [38] (10.2106/00004623-198466010-00012)
  • [L4] This patient has the longest disease-free interval of a metachronous multicentric giant cell tumor reported to date, with 24 years passing between the initial presentation and the multicentric recurrence. [43] (10.1097/01.blo.0000068770.86536.e1)
  • [L3] [56] (10.1054/jhsb.2000.0522)
  • [Case_report] The use of a massive biocompatible bipolar unconstrained prosthesis is a viable treatment option for distal radius reconstruction after en-bloc resection of a giant cell tumour, offering rapid functional improvement without donor-site morbidity. [62] (10.1016/j.otsr.2013.04.001)
  • [L3] Intralesional excision with local adjuvant therapy is recommended for the treatment of giant cell tumor of bone because it results in a good functional outcome compared to extralesional excision. [63] (10.1007/s004020100317)
  • [L4] [65] (10.1177/17531934231222401)
  • [L3] Repeated curettage with adjuvants eventually resulted in the cure for all patients and is therefore a reasonable treatment for both primary and recurrent GCT of the small bones of the hands and feet. [68] (10.1302/0301-620x.95b6.30876)
  • [L4] Reconstruction after wide excision by nonvascularized fibular graft is a viable alternative for giant cell tumors of the lower end of radius though it is a challenging procedure and may be accompanied by major complications. [73] (10.1007/s00402-010-1059-6)
  • [L4] Patients reported good functional outcomes without evidence of recurrence in a 19 patient cohort with an average follow-up of almost 7 years. [76] (10.1177/2325967119s00413)
  • [L4] Although MRI findings and location might help in the diagnosis of a T-GCT, careful assessment is mandatory, especially in unusual locations. [84] (10.1186/s12891-016-1050-7)
  • [L4] Radiologists should be familiar with this imaging characteristic. [87] (10.1186/s12891-021-04610-0)

References

[1] Radiation Therapy for Infiltrative Giant Cell Tumor of the Tendon Sheath. The Journal of Hand Surgery. 2012. DOI: 10.1016/j.jhsa.2012.01.011

[2] Giant cell tumors of the tendon sheaths in the hand: Review of 96 patients with an average follow-up of 12 years. Orthopaedics & Traumatology: Surgery & Research. 2013. DOI: 10.1016/j.otsr.2013.03.008

[3] Giant Cell Tumors of the Tendon Sheaths in the Hand: Review of 96 Patients With an Average Follow-Up of 12 Years. The Journal of Hand Surgery. 2013. DOI: 10.1016/j.jhsa.2013.08.051

[4] Giant cell tumour of hand bones: outcomes of treatment. Journal of Hand Surgery (European Volume). 2021. DOI: 10.1177/17531934211007820

[5] Management of a Rare Digital Dermocutaneous Fibroma of the Flexor Tendon Sheath. HAND. 2026. DOI: 10.1177/15589447261480384

[6] Is Intralesional Treatment of Giant Cell Tumor of the Distal Radius Comparable to Resection With Respect to Local Control and Functional Outcome?. Clinical Orthopaedics & Related Research. 2015. DOI: 10.1007/s11999-014-4054-3

[7] Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis. Journal of the American Academy of Orthopaedic Surgeons. 2025. DOI: 10.5435/jaaos-d-24-01255

[8] Fibroma of tendon sheath of the hand: a series of 20 patients with 23 tumours. Journal of Hand Surgery (European Volume). 2012. DOI: 10.1177/1753193412469146

[10] What Affects the Recurrence and Clinical Outcome of Pigmented Villonodular Synovitis?. Clinical Orthopaedics and Related Research. 2006. DOI: 10.1097/01.blo.0000224051.01873.fb

[11] Giant Cell Tumour of Tendon Sheath of the Digits. A Systematic Review. HAND. 2011. DOI: 10.1007/s11552-011-9341-9

[12] Giant cell tumor of tendon sheath in the hand: analysis of risk factors for recurrence in 50 cases. BMC Musculoskeletal Disorders. 2019. DOI: 10.1186/s12891-019-2866-8

[13] Functional Outcomes of Centralization of the Ulna as a Method of Reconstruction Following Resection of Campanacci Grade 3 Giant Cell Tumor of the Distal Radius. The Journal of Hand Surgery. 2024. DOI: 10.1016/j.jhsa.2022.05.011

[15] Giant Cell Tumor of Bone: Are We Stratifying Results Appropriately?. Clinical Orthopaedics & Related Research. 2012. DOI: 10.1007/s11999-011-2172-8

[17] Campanacci Grade 2 or 3 Giant Cell Tumor of the Phalanges: En Bloc Resection and Matched Nonvascularized Toe Phalangeal Transfer. The Journal of Hand Surgery. 2025. DOI: 10.1016/j.jhsa.2024.06.013

[18] Green S Operative Hand Surgery. BOX 59.1 Ganglions of the Hand and Wrist > Finger Metacarpals.

[21] Recurrence of Giant Cell Tumors in the Hand: A Prospective Study. The Journal of Hand Surgery. 2010. DOI: 10.1016/j.jhsa.2009.12.004

[22] Fibrous Xanthoma of Synovium (Giant-Cell Tumor of Tendon Sheath, Pigmented Nodular Synovitis). The Journal of Bone & Joint Surgery. 1969. DOI: 10.2106/00004623-196951010-00005

[23] Giant Cell Tumor of Tendon Sheath: Case Series and Review of Literature. Journal of Hand and Microsurgery. 2010. DOI: 10.1007/s12593-010-0020-9

[24] Extensor Carpi Ulnaris Tenodesis Versus No Stabilization After Wide Resection of Distal Ulna Giant Cell Tumors. HAND. 2017. DOI: 10.1177/1558944717743598

[25] Giant cell tumor of tendon sheath: study of 64 cases and review of literature. Giornale di Chirurgia - Journal of Surgery. 2013. DOI: 10.11138/gchir/2013.34.5.149

[26] Recurrent Pigmented Villonodular Synovitis and Multifocal Giant Cell Tumor of the Tendon Sheath: Case Report. The Journal of Hand Surgery. 2015. DOI: 10.1016/j.jhsa.2014.11.010

[27] Which Treatment is the Best for Giant Cell Tumors of the Distal Radius? A Meta-analysis. Clinical Orthopaedics & Related Research. 2012. DOI: 10.1007/s11999-012-2464-7

[35] Local recurrences after curettage and cementing in long bone giant cell tumor. Indian Journal of Orthopaedics. 2011. DOI: 10.4103/0019-5413.77138

[37] Results of Giant Cell Tumor of Bone Treated With Intralesional Excision. Clinical Orthopaedics & Related Research. 2004. DOI: 10.1097/01.blo.0000128280.59965.e3

[38] Pigmented villonodular synovitis (giant-cell tumor of the tendon sheath and synovial membrane). A review of eighty-one cases.. The Journal of Bone & Joint Surgery. 1984. DOI: 10.2106/00004623-198466010-00012

[43] Metachronous Multicentric Giant Cell Tumor: A Case Report and Literature Review. Clinical Orthopaedics & Related Research. 2003. DOI: 10.1097/01.blo.0000068770.86536.e1

[56] Giant Cell Tumours of Tendon Sheath: Classification and Recurrence Rate. Journal of Hand Surgery. 2001. DOI: 10.1054/jhsb.2000.0522

[62] Massive wrist prosthesis for giant cell tumour of the distal radius: A case report with a 3-year follow-up. Orthopaedics & Traumatology: Surgery & Research. 2013. DOI: 10.1016/j.otsr.2013.04.001

[63] Oncologic and functional results after treatment of giant cell tumors of bone. Archives of Orthopaedic and Trauma Surgery. 2001. DOI: 10.1007/s004020100317

[65] The effect of surgical factors on recurrence of tendon sheath giant cell tumours. Journal of Hand Surgery (European Volume). 2024. DOI: 10.1177/17531934231222401

[68] Giant cell tumours of the small bones of the hands and feet. The Bone & Joint Journal. 2013. DOI: 10.1302/0301-620x.95b6.30876

[73] Autogenous non-vascularized fibula for treatment of giant cell tumor of distal end radius. Archives of Orthopaedic and Trauma Surgery. 2010. DOI: 10.1007/s00402-010-1059-6

[76] Pigmented Villonodular Synovitis of the Hip Managed with Arthroscopic Synovectomy: An Analysis of 19 Cases with up to 10-year Follow-up. Orthopaedic Journal of Sports Medicine. 2019. DOI: 10.1177/2325967119s00413

[84] Tenosynovial giant cell tumors in unusual locations detected by positron emission tomography imaging confused with malignant tumors: report of two cases. BMC Musculoskeletal Disorders. 2016. DOI: 10.1186/s12891-016-1050-7

[87] Giant cell tumors of the mobile spine with invasion of adjacent vertebrae: an unusual imaging finding. BMC Musculoskeletal Disorders. 2021. DOI: 10.1186/s12891-021-04610-0

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International

Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees

Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.